Australian contract research organisation Molecule2Market has appointed Dr Julie Ince-Demetriou as its first Chief Executive Officer, marking a pivotal moment in the company’s evolution as it enters a new phase of growth and operational scale.
Molecule2Market is a global-ready clinical research organisation dedicated to advancing Australia’s role in the development of innovative medical treatments, providing streamlined solutions for both emerging biotechnology companies and established life sciences organisations.
Based in Melbourne, the company has experienced sustained expansion driven by increasing demand for high-quality, flexible clinical research support across the life sciences sector.
The creation of a dedicated CEO role reflects both the growing complexity of the organisation and its ambition to strengthen leadership capacity while preserving the scientific integrity and culture that have underpinned its success to date.
Dr Ince-Demetriou brings extensive clinical research expertise and a strong track record in strategic leadership, with experience scaling organisations in a sustainable and values-driven way. She is widely recognised for building high-performing teams, translating strategy into execution, and fostering collaborative partnerships across the life sciences ecosystem.
Molecule2Market Directors Anne De Luca and Robin Hansen will continue to play an active role in governance and long-term strategy, working closely with Dr Ince-Demetriou as the organisation moves into its next chapter. According to Hansen, the appointment represents a natural progression for the company, strengthening its leadership structure while ensuring that the founding vision and values remain firmly in place.
De Luca emphasised the importance of maintaining culture alongside growth, noting that Dr Ince-Demetriou’s people-centred leadership style and commercial acumen align closely with Molecule2Market’s core principles.
Commenting on her appointment, Dr Ince-Demetriou said she was excited to step into the role at a pivotal time for the organisation. She highlighted Molecule2Market’s strong reputation for scientific excellence and integrity, and expressed her enthusiasm for working with the Board, team, and clients to support continued growth and impact.